GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

Have a nice week! It’s hard to know exactly what change in Washington will mean for the health care industry starting next ...